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Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Phþ) acute lymphoblastic leukaemia (ALL) are
caused by the BCR-ABL oncogene. Imatinib inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline
therapy for chronic-phase CML. However, accelerated or blast-crisis phase CML patients and Phþ ALL patients often relapse due to
drug resistance resulting from the emergence of imatinib-resistant point mutations within the BCR-ABL tyrosine kinase domain. This
has stimulated the development of new kinase inhibitors that are able to over-ride resistance to imatinib. The novel, selective BCR-
ABL inhibitor, AMN107, was designed to fit into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib. In
addition to being more potent than imatinib (IC50o30nM) against wild-type BCR-ABL, AMN107 is also significantly active against
32/33 imatinib-resistant BCR-ABL mutants. In preclinical studies, AMN107 demonstrated activity in vitro and in vivo against wild-type
and imatinib-resistant BCR-ABL-expressing cells. In phase I/II clinical trials, AMN107 has produced haematological and cytogenetic
responses in CML patients, who either did not initially respond to imatinib or developed imatinib resistance. Dasatinib (BMS-354825),
which inhibits Abl and Src family kinases, is another promising new clinical candidate for CML that has shown good efficacy in CML
patients. In this review, the early characterisation and development of AMN107 is discussed, as is the current status of AMN107 in
clinical trials for imatinib-resistant CML and Phþ ALL. Future trends investigating prediction of mechanisms of resistance to
AMN107, and how and where AMN107 is expected to fit into the overall picture for treatment of early-phase CML and imatinib-
refractory and late-stage disease are discussed.
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Chronic myelogenous leukaemia (CML) constitutes 15% of adult
leukaemias, with approximately 4600 newly diagnosed cases per
annum in the United States. The initial, chronic phase of the
disease has a median duration of 4–6 years and is characterised by
overproduction of immature myeloid cells and mature granulo-
cytes in the spleen, bone marrow, and peripheral blood. Without
therapeutic intervention, after a mean latency period of 4–6 years,
the disease progresses via an accelerated phase, marked by the
presence of primitive blast cells in the bone marrow and peripheral
blood, and finally advances to the ‘blast-crisis’ phase, characterised
by over 30% undifferentiated blasts in the bone marrow and
peripheral blood, and for which median survival is 18 weeks
(Kantarjian and Talpaz, 1988).
The BCR-ABL oncogene, which results from a reciprocal t(9;22)
chromosomal translocation, encodes a chimeric BCR-ABL protein
having constitutively activated Abl tyrosine kinase activity, and is
the underlying cause of CML (Bartram et al, 1983; Groffen et al,
1984; Lugo et al, 1990). The 210kDa BCR-ABL protein is expressed
in CML patients, whereas a 190kDa BCR-ABL protein, resulting
from an alternative breakpoint in the BCR gene, is expressed in
Phþ acute lymphoblastic leukaemia (ALL) patients (Chan et al,
1987).
The discovery that CML is due to the activity of BCR-ABL
prompted the design and development Novartis Pharma AG,
WKL-136.7.86, Klybeckstrasse 141, CH-4057 Basel, Switzerland of
imatinib (Glivec
s, Gleevect, STI571; Novartis Pharma AG), a
small molecule kinase inhibitor that targets the PDGFR, c-Kit and
Abl kinases (Druker et al, 1996; Buchdunger et al, 2000). Imatinib
provides an effective and durable therapy for CML, inducing
complete haematologic remissions (normal leucocyte count in
peripheral blood) in the majority (98%) of newly diagnosed
patients in the chronic phase of the disease, and complete
cytogenetic responses (no detectable Phþ cells from X20 bone
marrow cells in metaphase) in a high percentage (86%) of patients
(Simonsson, 2005). Primary resistance to imatinib only occurs
occasionally in chronic-phase CML patients, and recent analysis of
the IRIS study shows a low and decreasing annual rate of
progression (resulting in death) after 1, 2, 3 and 4 years of therapy
of 3.4, 7.5, 4.8 and 1.5%, respectively, possibly as a result of
patients with the worse prognosis progressing relatively early. In
39% of newly diagnosed chronic-phase CML patients, therapy with
a standard dose of imatinib for 12 months leads to a major
molecular response comprising of 1000-fold reduction in BCR-ABL
transcript levels, which is associated with a reduced risk of disease
progression (Hughes et al, 2003). However, advanced (accelerated
or blast crisis) phase CML and Phþ ALL patients show
significantly decreased response rates to treatment with imatinib
monotherapy, with relapse common within a year (Ottmann et al,
2002; Sawyers et al, 2002); acquired resistance is less commonly
observed in the case of newly diagnosed Phþ ALL patients
receiving combination therapy with chemotherapy.
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www.bjcancer.comResistance frequently results from the emergence of point
mutations within the kinase domain of the BCR-ABL protein that
reduce the binding affinity of imatinib, although it is occasionally
associated with amplification of the BCR-ABL gene (Gorre et al,
2001). Most mutations that confer resistance to imatinib are
distributed throughout the Abl kinase domain. However, the most
resistant ones, such as many of those found in the P-loop, often
occur at or near residues that are in direct contact with the drug.
The degree of resistance ranges from a few fold for some of the
A-loop mutants, up to complete resistance for the T315I mutation,
which precludes imatinib from binding. Overall, the steady rate
of developing resistance to imatinib has suggested that new
kinase inhibitors could be of clinical value, particularly if they
could override imatinib resistance and bind with higher affinity to
BCR-ABL.
AMN107 (NILOTINIB)
Rational design of novel inhibitors exhibiting effectiveness against
imatinib-resistant mutants of BCR-ABL was carried out by
researchers at Novartis Pharmaceuticals, based upon the crystal
structure of the imatinib-Abl complex (Schindler et al, 2000; Nagar
et al, 2002; Manley et al, 2004). It was hypothesised that the
potency and selectivity of imatinib (Figure 1F) could be improved
by maintaining binding to the inactive conformation of the Abl
kinase domain, but incorporating alternative binding groups to the
N-methylpiperazine moiety, while preserving an amide pharma-
cophore to retain H-bond interactions to Glu286 and Asp381. This
led to the development of AMN107 (nilotinib; Figure 1E), a high-
affinity aminopyrimidine-based ATP-competitive inhibitor that
decreases proliferation and viability of wild-type BCR-ABL- and
imatinib-resistant BCR-ABL mutant-expressing cells in vitro by
selectively inhibiting BCR-ABL autophosphorylation (Table 1).
AMN107 exhibits superior potency to imatinib as an inhibitor of
wild-type BCR-ABL in a wide range of CML-derived and
transfected cell lines (Golemovic et al, 2005; Weisberg et al,
2005). This in vitro profile translates into in vivo efficacy, where
AMN107 has been shown to prolong the survival of mice injected
with BCR-ABL-transformed haematopoietic cell lines or primary
marrow cells, and to prolong survival in imatinib-resistant CML
mouse models (Weisberg et al, 2005).
As well as being designed to bind more tightly to the BCR-ABL
protein in an attempt to enhance efficacy, AMN107 was intended
to over-ride resistance caused by mutations. Crystallographic
studies of AMN107 indeed suggest that subtle differences in the
mode of binding to Abl and a better topological fit to the Abl
protein account for the greater potency of the drug (Weisberg et al,
2005). Like imatinib, AMN107 binds to the inactive conformation
of the Abl tyrosine kinase, with P-loop folding over the ATP-
binding site, and the activation-loop blocking the substrate
binding site, to disrupt the ATP-phosphate-binding site and
inhibit the catalytic activity of the enzyme (Figure 1C) (Manley
et al, 2005). AMN107 makes four hydrogen-bond interactions with
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Figure 1 Structures of Abl kinase (A) in the active (Fendrich et al, 2006) and (C) inactive states, with dasatinib (blue) docked and nilotinib (magenta) as
bound in the crystal structure (Weisberg et al, 2005), respectively. The differing conformations of the glycine-rich or P-loop (yellow) and the activation loop
(green) are induced or stabilised by the different binding modes of the two inhibitors. (B) shows a superposition of the two distinct conformations,
emphasising how dasatinib and nilotinib occupy different parts of the cleft between the N- (upper) and C-terminal (lower) lobes of the kinase. The
corresponding aspects of the molecular structures of (D) dasatinib and (E) nilotinib are depicted, with their respective H-bond interactions with the Abl
kinase domain indicated in red, in comparison to imatinib (F).
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backbone-NH of Met318, the anilino-NH and the side-chain
hydroxyl of Thr315, the amido-NH and side-chain carboxylate of
Glu286, as well as the amido-C¼O and backbone-NH of Asp381,
to induce the inactive conformation of BCR-ABL (Figure 1C)
(Manley et al, 2005). However, the many lipophilic interactions are
also important for affinity, as is the interaction between the
backbone-C¼O of Asp381 and a fluorine atom in the trifluoro-
methyl group of AMN107 (Manley et al, 2005).
AMN107 is X20-fold more potent than imatinib in the killing of
wild-type BCR-ABL-expressing cells (Table 1) (Manley et al, 2005;
O’Hare et al, 2005; Weisberg et al, 2005). Studies involving the
imatinib-sensitive cell lines KBM5 and KBM7 show AMN107 to be
43- and 60 times more potent than imatinib, respectively
(Golemovic et al, 2005). AMN107 maintains activity against
32/33 imatinib-resistant BCR-ABL mutants, but has no significant
activity against the T315I mutant (Table 1) (Manley et al, 2005;
O’Hare et al, 2005; Weisberg et al, 2005). As with imatinib, the lack
of activity against the T315I mutant is the result of AMN107
binding closely to the T315 residue, such that loss of the hydroxyl
side chain and additional methyl group of the isoleucine inhibits
binding (Figure 1E and F).
In a dose-escalating Phase I study, imatinib-resistant CML
patients in the chronic phase (17 patients), accelerated phase (46
patients) and blast crisis (33 patients), together with 13 Phþ ALL
patients, were treated with AMN107 (50–1200mgday
 1) for up to
385 days (Kantarjian et al, 2006). The maximum tolerated dose was
determined to be 600mg b.i.d., with frequently noted side effects
being myelosuppression, mild-moderate skin rash and transient
indirect hyperbilirubinaemia. In this study, AMN107 was not
associated with the oedema frequently associated with imatinib.
Among patients with chronic, accelerated and blast-phase CML,
haematological/cytogenetic responses were achieved in 92/53,
72/48 and 39/27%, respectively. The best responses were seen at
doses X400mg q.d. and with 400mg b.i.d. Two of the imatinib-
resistant Phþ ALL patients also responded. Pharmacokinetic
analysis of patients receiving 400mg b.i.d., which was the dose
selected for Phase II trials, showed mean peak-trough plasma
levels of 3.6 and 1.7mM, respectively, with an apparent half-life of
15h. Based upon the in vitro data, this level of drug exposure
would be expected to result in clinical activity against most of the
mutants characterised in Table 1, with the exception of T315I, and
is therefore consistent with the responses observed in patients
harbouring imatinib-resistant point mutations.
Table 1 Comparison of imatinib and AMN107 for effects on autophosphorylation and proliferation in Ba/F3 cells transfected to express native BCR-ABL-
or imatinib-resistant mutant forms of the enzyme
Imatinib AMN107
BCR-ABL form (construct) Autophosphorylation Proliferation Autophosphorylation Proliferation
Wild-type p210+IL-3 NA 47700 (4) NA 410000 (15)
Wild-type p210 221731 (14) 678739 (23) 2072 (7) 2571 (68)
M237I (p185) 399 (2) 1545 (2) 4178.3 (3) 4378.7 (3)
M244V (p185) 937 (2) 2036 (2) 101716 (3) 6777 (4)
L248V (p185) 1011 (2) 2081 (2) 8377 (3) 102713 (4)
G250A (p185) 313 (2) 1269 (2) 58711 (3) 6575.6 (3)
G250E (p185) 22877826 (4) 332971488 (2) 92710 (5) 145732 (3)
G250V (p185) 489 (2) 624 (2) 66712 (3) 1971.4 (3)
Q252H (p185) 10807119 (2) 8517436 (2) 117725 (3) 67722 (4)
Y253H (p185) 410000 (2) 47000 (2) 260734 (6) 7007116 (5)
E255D (p185) 754 (2) 1082 (2) 5174.8 (3) 2773.1 (3)
E255K (p185) 48567482 (4) 5567 (2) 392782 (6) 308742 (5)
E255K (p210) 24557433 (4) 71617970 (3) 15379 (4) 548772 (6)
E255R (p185) 1877 (2) 1567 (2) 24076.5 (3) 5874.2 (3)
E255V (p210) 63537636 (14) 61117854 (12) 244722 (13) 791767 (19)
E275K (p185) 1038 (2) 563 (2) 12575.0 (3) 44717.1 (3)
D276G (p185) 1284 (2) 2486 (2) 10779.1 (3) 69710 (3)
E281K (p185) 584 (2) 1601 (2) 4276.5 (3) 4079.8 (3)
K285N (p185) 919 (2) 1264 (2) 204719 (3) 57712 (3)
E292K (p210) 275781 (3) 1552 (2) 3176 (3) 8178 (4)
F311V (p185) 1480 (2) 3535 (2) 8472 (3) 155731 (4)
T315I (p210) 410000 (22) 47000 (17) 410000 (48) 410000 (51)
F317C (p185) 1090 (2) 694 (2) 69713 (3) 2073.1 (3)
F317L (p210) 797792 (11) 15287227 (15) 3874 (13) 9176.5 (17)
F317V (p185) 544747 (3) 5497173 (4) 95728 (3) 2874 (4)
D325N (p185) 584 (2) 887 (2) 7079.0 (3) 2672.7 (3)
S348L (p185) 553 (2) 1370 (2) 5571.3 (3) 2674.8 (3)
M351T (p210) 593757 (11) 16827233 (18) 2973 (13) 3874 (18)
E355A (p185) 676 (2) 1434 (2) 90717 (3) 3576.7 (3)
E355G (p185) 601 (2) 1149 (2) 67715 (3) 4778 (4)
F359C (p185) 1130 (2) 2377 (2) 217717 (3) 258761 (3)
F359V (p185) 1528 (2) 595 (2) 313779 (3) 161761 (4)
A380S (p185) 2617 (2) 3744 (2) 135711 (3) 164727 (3)
L387F (p185) 530 (2) 172 (2) 197725 (3) 4677.2 (3
M388L (p185) 517 (2) 525 (2) 73716 (3) 1872.6 (3)
F486S (p210) 12387110 (11) 30507597 (10) 4174 (8) 7577 (11)
The influence of compounds on kinase autophosphorylation or cell viability was calculated as percentage inhibition as described (Weisberg et al, 2005). Dose–response curves
were used to calculate IC50 values, expressed as mean7s.e.m. (nM) (number of replicates). The influence of compounds on BCR-ABL autophosphorylation or cell viability was
determined with capture ELISAs or the ATPlitet assay kit (Perkin-Elmer), respectively. Dose–response curves (per cent inhibition) were used to calculate IC50 values, expressed
as mean7s.e.m., n¼number of experiments.
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that AMN107 will have substantial clinical utility in rescuing
patients who develop imatinib resistance due to point mutations,
and could potentially be used as a single agent in patients at risk
for progression. Additionally, there is growing interest in testing
the hypothesis that administration of multiple Abl kinase
inhibitors in early-phase patients, such as AMN107, dasatinib
(Shah et al, 2005) and imatinib, could be used to delay or prevent
the emergence of drug-resistant clones. In support of these ideas,
additive/synergistic toxicity against both imatinib-sensitive and
imatinib-resistant BCR-ABL-expressing cells has been reported
following coadministration of AMN107 and imatinib, in vitro and
in vivo (Griffin and Weisberg, 2005; Weisberg et al, 2005). Such
effects might result from pharmacodynamic effects, and prelimin-
ary data suggest that synergy between imatinib and AMN107 may
occur at the level of the CML stem cell due to the ability of both
imatinib and AMN107 to inhibit or act as substrates of the
multidrug efflux transporter ABCG2, which confers resistance
toward several anticancer drugs (Jorgensen et al, 2005). A recent
report also suggests that imatinib and AMN107 are taken up in
cells by different mechanisms, with the influx, intracellular
concentrations of imatinib, and consequently patient sensitivity
to imatinib depending upon the organic cation transporter Oct-1,
whereas AMN107 transport appears to be independent of Oct-1
(White et al, 2006). However, since the T315I mutation of BCR-
ABL is highly resistant to imatinib, AMN107 and dasatinib, this
approach needs to be extended to include inhibitors of T315I BCR-
ABL to prevent this mutation from becoming more prevalent.
Alternatively, it is also important to explore the potential for
synergy between AMN107 and other classes of inhibitors that work
through mechanisms not involving inhibition of Abl tyrosine
kinase activity.
To aid the selection of patients most likely to benefit and
show clinical responses to single agents, as well as to assess
which drug combinations might be most appropriate, it is
important to be able to predict resistance mechanisms and
establish the resistance profiles of the available BCR-ABL
inhibitors. Although overexpression of BCR-ABL is a possible
resistance mechanism for AMN107 (Mahon et al, 2004), resistance
is more likely to arise through the emergence of clones expressing
AMN107-resistant mutant forms of BCR-ABL. A cell-based
screening assay designed to predict such mutations has
recently been applied to AMN107 (Von Bubnoff et al, 2006).
Using this system, a reduced pattern of mutations was observed
for AMN107, having some overlap with that seen for imatinib:
Q252H, Y253H, E255K(V), F311I, T315I, S349L and F359I(V), all of
which, with the exception of the T315I mutant, were suppressed at
clinically achievable concentrations of AMN107. In an alternative
cell-line-based mutagenesis study, the emergence of BCR-ABL
mutations resistant to imatinib, AMN107 and dasatinib were
compared: 18 mutations were recovered with imatinib, nine
mutations (G250E, Y253H, E255K(V), E292V, T351I, F359C,
L384M and L387F) were recovered with AMN107, and six
mutations (E255K, L284V, V299L, T315I and F317I(V)) were
recovered with dasatinib (Deininger et al, 2005). In a similar
mutagenesis study with dasatinib (Shah et al, 2005), 10 resistance
mutants of BCR-ABL involving six residues were isolated: L248R,
Q252H, E255K, V299L, F317L/V/I/S and T315I/A. BCR-ABL point
mutations conferring resistance to AMN107 have also been
identified in a random mutagenesis study (Ray et al, 2005). In
this study, 11 novel mutations were detected (K247N, L248V,
L273F, E282K, K285N, V289L, E292K, N297T, H375P, T406I and
W430L), in addition to five (Q252H, Y253C(H), E255K and T315I),
which have been previously observed in CML patients treated with
imatinib. Although these studies do not consistently identify the
same drug-resistant BCR-ABL point mutations for individual
drugs, it is clear that all three compounds display different
mutagenicity profiles.
Since the pattern of arising BCR-ABL mutants should be
associated with the binding mode of that particular compound
to the Abl protein, conceptually, the greatest benefit from a
combination of two such agents should be achieved using
compounds having the greatest difference between their
binding modes. Thus, whereas both imatinib and AMN107 bind
to an inactive conformation of Abl (Figure 1C), dasatinib has
been shown to bind to the active conformation (Figure 1A),
and this can be invoked to explain the differences observed in the
mutagenesis studies with these compounds. Therefore, a combina-
tion between dasatinib and AMN107 (or imatinib) might be
expected to impart the greatest benefit (cf. Figure 1B), since
dasatinib might inhibit many AMN107/imatinib-resistant mutants
and conversely AMN107/imatinib might inhibit many dasatinib-
resistant mutants.
Other studies have uncovered additional targets of AMN107
that help to elucidate its mechanism of action and/or suggest
additional disease targets. Both AMN107 and imatinib have
been observed to promote the expression of Bcl-2-interacting
mediator, a tumour suppressor reported to be underexpressed in
primary CML cells in comparison to normal cells (Aichberger
et al, 2005). The ability of AMN107 to inhibit TEL-platelet-derived
growth factor receptor-beta (TEL-PDGFRbeta), which causes
chronic myelomonocytic leukaemia, and FIP1-like-1-PDGFRalpha,
which causes hypereosinophilic syndrome, suggests potential
use of AMN107 for myeloproliferative diseases characterised
by these kinase fusions (Stover et al, 2005; Weisberg et al,
2005). AMN107 also inhibits the c-Kit receptor kinase, including
the D816V-mutated variant of KIT, at pharmacologically
achievable concentrations, supporting potential utility in
the treatment of mastocytosis, and gastrointestinal stromal
tumours (Weisberg et al, 2005; von Bubnoff et al, 2005; Gleixner
et al, 2006).
CONCLUSION
Preclinical and early-phase clinical findings indicate that
AMN107 may be useful in the treatment of imatinib-refractory
CML. This is due to its strong binding affinity to Abl, its
activity against imatinib-resistant BCR-ABL point mutants, and
its efficacy and tolerability in clinical studies. Greater than 70%
of CML patients with advanced disease and over 90%
of early, chronic-phase patients have responded to AMN107,
and response rates continue to increase with overall good
tolerability. In order to evaluate AMN107 in newly diagnosed
CML, a study has recently been initiated (MD Anderson Cancer
Center, Houston).
The failure of some patients to respond to AMN107, especially
those with more advanced disease, might arise due to development
of new mutations that impede the interaction between AMN107
and BCR-ABL. Thus, the identification and characterisation of
BCR-ABL point mutants conferring resistance to AMN107 will
assist in the prediction of patient responses to AMN107,
identifying combination partners, as well as in the design and
development of novel inhibitors of BCR-ABL that can over-ride
resistance to such mutants. The preclinical and clinical evaluation
of combinations of AMN107 with other approved or investiga-
tional inhibitors of Abl and additional signaling pathways will be
helpful in the development of therapeutic strategies designed to
over-ride drug resistance.
Both the safety and effectiveness of AMN107 are currently being
evaluated in clinical trials involving CML patients that are
intolerant of, or refractory to, imatinib. Thus far, AMN107 is
showing promise as a potential therapeutic for CML at all levels of
the disease. The frequency of use of AMN107 as a treatment for
CML and Phþ ALL will depend on its safety/efficacy profiles in
clinical trials.
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